Company Info

Astellas

Drug Discovery & Development

Overview

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Contributions

Contributors

Contributions

11 Contributions1 / 1

M&A

Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.

Astellas

PR-M01-20-NI-006Jan 03, 2020

License Agreement

Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss

Astellas

PR-M07-19-NI-055Jul 22, 2019

BLA

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin

Astellas

PR-M07-19-NI-050Jul 19, 2019

Launch

Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients

Astellas

PR-M03-19-NI-051Mar 19, 2019

Collaboration

Astellas and WiserCare Announce Collaboration to Improve Patient Experience

Astellas

PR-M02-19-NI-057Feb 26, 2019

Launch

Astellas Launches XOSPATA® (gilteritinib) in the U.S. for the Treatment of Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

Astellas

PR-M12-18-NI-057Dec 17, 2018

Leukemia

Astellas Presents Updated Results from Phase 1 Study of Gilteritinib Plus Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Astellas

PR-M12-18-NI-025Dec 07, 2018

Launch

Astellas Global Health Foundation Launches

Astellas

PR-M11-18-NI-087-3340Nov 26, 2018

FDA Approval

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Astellas

PR-M07-18-NI-047Jul 16, 2018

Appointment

Astellas names Nahrin Marino to Vice President, Head of Ethics & Compliance Americas

Astellas

PR-M06-18-NI-031Jun 11, 2018

FDA

U.S. FDA Grants Priority Review for a Supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) in Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Astellas

PR-M03-18-NI-085Mar 23, 2018

1 / 1

0 Contributors1 / 0

No authors found

1 / 0